See more : Alkim Alkali Kimya A.S. (ALKIM.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Imeik Technology Development Co.,Ltd. (300896.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imeik Technology Development Co.,Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Upstream Bio, Inc. (UPB) Income Statement Analysis – Financial Results
- Immotion Group Plc (IMMO.L) Income Statement Analysis – Financial Results
- Bendigo and Adelaide Bank Limited (BEN.AX) Income Statement Analysis – Financial Results
- NextEra Energy, Inc. (NEE-PQ) Income Statement Analysis – Financial Results
- Bridgestone Corporation (5108.T) Income Statement Analysis – Financial Results
Imeik Technology Development Co.,Ltd. (300896.SZ)
About Imeik Technology Development Co.,Ltd.
Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials. The company offers medical beauty field products, including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. It also offers skin care products, including moisturizing lotions, anti-wrinkle firming kinetic energy liquids, essence creams, hydrating firming masks, chitosan B5 repair sprays, and purifying and brightening kinetic liquids. The company was founded in 2004 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.87B | 1.94B | 1.45B | 709.29M | 557.72M | 321.01M | 222.49M | 140.73M | 111.82M | 75.12M |
| Cost of Revenue | 140.77M | 99.91M | 91.27M | 58.12M | 41.10M | 34.22M | 30.82M | 18.02M | 9.72M | 4.71M |
| Gross Profit | 2.73B | 1.84B | 1.36B | 651.17M | 516.62M | 286.80M | 191.67M | 122.71M | 102.10M | 70.41M |
| Gross Profit Ratio | 95.09% | 94.85% | 93.70% | 91.81% | 92.63% | 89.34% | 86.15% | 87.19% | 91.31% | 93.73% |
| Research & Development | 250.13M | 173.11M | 102.31M | 61.80M | 48.56M | 33.68M | 28.49M | 13.08M | 5.73M | 4.43M |
| General & Administrative | 55.17M | 72.40M | 23.25M | 21.92M | -57.25M | -43.29M | -28.98M | 18.53M | 45.99M | 19.48M |
| Selling & Marketing | 85.54M | 162.67M | 156.49M | 70.95M | 77.17M | 62.41M | 41.91M | 29.65M | 27.88M | 16.60M |
| SG&A | 140.71M | 235.07M | 179.73M | 92.87M | 19.92M | 19.11M | 12.92M | 48.18M | 73.88M | 36.08M |
| Other Expenses | 179.53M | 47.65M | 43.11M | 23.52M | 106.06M | -3.51M | -1.39M | 1.40M | 648.85K | 1.24M |
| Operating Expenses | 570.37M | 455.84M | 325.16M | 178.20M | 174.55M | 144.92M | 99.04M | 63.57M | 75.91M | 37.44M |
| Cost & Expenses | 711.13M | 555.75M | 416.42M | 236.32M | 215.65M | 179.13M | 129.86M | 81.60M | 85.62M | 42.16M |
| Interest Income | 58.25M | 48.68M | 54.21M | 14.40M | 5.29M | 5.84M | 2.43M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.38M | 3.15M | 2.14M | 62.96K | 58.19K | 512.60K | 216.43K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.49M | 28.62M | 19.71M | 11.08M | 10.06M | 11.70M | 2.82M | 1.45M | 891.90K | 703.20K |
| EBITDA | 2.20B | 1.52B | 1.14B | 482.22M | 352.11M | 155.10M | 96.28M | 61.23M | 27.09M | 32.97M |
| EBITDA Ratio | 76.56% | 78.31% | 79.06% | 68.13% | 64.82% | 49.87% | 44.42% | 42.57% | 25.26% | 45.75% |
| Operating Income | 2.16B | 1.49B | 1.13B | 502.74M | 350.21M | 143.27M | 93.70M | 62.04M | 27.18M | 33.07M |
| Operating Income Ratio | 75.22% | 76.76% | 77.81% | 70.88% | 62.79% | 44.63% | 42.11% | 44.09% | 24.31% | 44.03% |
| Total Other Income/Expenses | -2.66M | 106.83K | -4.78M | -85.68K | 580.88K | -74.18K | 2.79K | 1.43M | 582.85K | 1.24M |
| Income Before Tax | 2.16B | 1.49B | 1.12B | 502.66M | 350.79M | 143.19M | 93.70M | 63.44M | 27.76M | 34.31M |
| Income Before Tax Ratio | 75.12% | 76.76% | 77.48% | 70.87% | 62.90% | 44.61% | 42.12% | 45.08% | 24.83% | 45.67% |
| Income Tax Expense | 300.64M | 220.72M | 164.50M | 69.27M | 52.82M | 27.06M | 16.97M | 10.34M | 10.11M | 5.89M |
| Net Income | 1.86B | 1.26B | 957.98M | 439.75M | 305.52M | 122.85M | 82.19M | 53.38M | 17.65M | 28.42M |
| Net Income Ratio | 64.77% | 65.17% | 66.16% | 62.00% | 54.78% | 38.27% | 36.94% | 37.93% | 15.79% | 37.83% |
| EPS | 6.14 | 5.84 | 4.43 | 2.03 | 1.41 | 0.76 | 0.51 | 0.34 | 0.11 | 0.18 |
| EPS Diluted | 6.14 | 5.84 | 4.43 | 2.03 | 1.41 | 0.76 | 0.51 | 0.34 | 0.11 | 0.18 |
| Weighted Avg Shares Out | 302.54M | 216.36M | 216.36M | 216.36M | 216.36M | 161.42M | 162.57M | 154.97M | 154.97M | 154.97M |
| Weighted Avg Shares Out (Dil) | 302.54M | 216.36M | 216.36M | 216.36M | 216.36M | 161.42M | 162.58M | 154.97M | 154.97M | 154.97M |
Source: https://incomestatements.info
Category: Stock Reports